Search research articles
Contact Us
Filters
Showing results (51-60 of 93) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Investigational New Drugs
|
August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk, Glenn Liu, Walter M Stadler, et al.
British Journal of Cancer
|
January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study
Joe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 19, 2023
Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients
Ulka N Vaishampayan, Lance Heilbrun, Nitin Vaishampayan, et al.
Nature Communications
|
March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Journal for Immunotherapy of Cancer
|
December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
Brian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
Daniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 93) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Investigational New Drugs
|
August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk, Glenn Liu, Walter M Stadler, et al.
British Journal of Cancer
|
January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study
Joe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 19, 2023
Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients
Ulka N Vaishampayan, Lance Heilbrun, Nitin Vaishampayan, et al.
Nature Communications
|
March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Journal for Immunotherapy of Cancer
|
December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
Brian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
Daniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
Page
of 10